Aquilo Capital Management, LLC
In its 13F for Q2 2024 (holdings as of June 30, 2024, filed August 14, 2024), Aquilo Capital Management, LLC reported 13 stock positions worth $103.7 million. Its top holding was Arrowhead Pharmaceuticals (ARWR) at 22.8% of the portfolio, followed by Blueprint Medicines (BPMC, 11.9%) and Arvinas (ARVN, 11.0%). Compared with Q1 2024, it opened 3 new positions, added to 2 and reduced 6. The biggest buy was a new position in Bicycle Therapeutics PLC-ADR (BCYC) and the biggest sale Sutro Biopharma Inc. Com SHS (STRO, shares −35%).
- Most Recent 13F
- Q3 2025
- Location
- SAN FRANCISCO, CA
- CIK
- 0001591986
- Portfolio Value
- $103.7M (Q2 2024)
- SEC Filing
- 0001591986-24-000006 ↗ filed Aug 14, 2024
Holdings Value
Holdings 13 stocks · $103.7M
| ARWR Arrowhead Pharmaceuticals Inc. | 22.76% | 908,474 | $23.6M | No change |
| BPMC Blueprint Medicines Corp. | 11.91% | 114,600 | $12.4M | Reduce -37.1% |
| ARVN Arvinas Inc. | 11.00% | 428,766 | $11.4M | Add +5.7% |
| RGNX Regenxbio Inc. | 10.22% | 906,248 | $10.6M | No change |
| KYMR Kymera Therapeutics Inc. | 9.46% | 328,743 | $9.8M | Reduce -15.4% |
| SLN Silence Therapeutics PLC-ADR | 9.16% | 500,214 | $9.5M | Reduce -12.9% |
| MRUS Merus NV | 8.45% | 148,109 | $8.8M | Reduce -41.9% |
| DTIL Precision Biosciences Inc. | 3.58% | 381,803 | $3.7M | Reduce -0.9% |
| BCYC Bicycle Therapeutics PLC-ADR | 3.06% | 156,692 | $3.2M | New |
| RPTX Repare Therapeutics Inc. | 3.04% | 956,932 | $3.2M | Add +51.1% |
| ACET Adicet Bio Inc. | 2.95% | 2,531,194 | $3.1M | New |
| IMTX Immatics NV | 2.24% | 200,000 | $2.3M | New |
| STRO Sutro Biopharma Inc. Com SHS | 2.15% | 762,498 | $2.2M | Reduce -34.6% |
Portfolio Sells Q1 2024 → Q2 2024
| STRO Sutro Biopharma Inc. Com SHS | Reduce -34.6% | 2.15% | −2.78 |
| KYMR Kymera Therapeutics Inc. | Reduce -15.4% | 9.46% | −2.25 |
| BPMC Blueprint Medicines Corp. | Reduce -37.1% | 11.91% | −1.04 |
| DTIL Precision Biosciences Inc. | Reduce -0.9% | 3.58% | −0.34 |
| MRUS Merus NV | Reduce -41.9% | 8.45% | −0.16 |
| SLN Silence Therapeutics PLC-ADR | Reduce -12.9% | 9.16% | −0.13 |